Common Side Effects Patients Report with Long-Term Vascepa
Vascepa (icosapent ethyl), used to lower triglycerides and reduce cardiovascular risk, shows these side effects in clinical trials and post-marketing data: joint pain (arthralgia, 2.3% vs 1.8% placebo), gout (1.1% vs 0.9%), constipation, and atrial fibrillation (5% vs 3.9% in REDUCE-IT trial). Most occur early but can persist with prolonged use.[1][2]
Does Prolonged Use Increase Bleeding Risk?
Bleeding events rise with long-term use—5.2% vs 3.8% placebo in REDUCE-IT over 4.9 years median follow-up, including epistaxis and hematuria. This links to its mechanism inhibiting platelet aggregation, especially if combined with anticoagulants like warfarin. No fatal bleeds reported, but monitor closely.[2][3]
What Happens with Liver or Muscle Issues Over Time?
Elevated liver enzymes (>3x ULN) occurred in 1.2% vs 0.6% placebo. Myalgia (muscle pain) and rhabdomyolysis are rare but flagged in labeling, particularly with statins. Long-term data from trials up to 7 years show no clear escalation, but FDA warns of potential in high-risk patients.[1][4]
Risks for Diabetes Patients on Vascepa Long-Term
Hyperglycemia worsened in 3.5% vs 2.9% placebo, with new diabetes onset in 3.7% vs 3.1%. Prolonged use may amplify glycemic effects in predisposed individuals, per EVAPORATE and REDUCE-IT extensions.[2][5]
How Do Real-World Studies Compare to Trials?
Post-approval data from over 1 million patients (via FDA Sentinel) confirm low serious event rates, but prolonged use (>1 year) correlates with higher atrial fibrillation and bleeding reports. No new signals for cancer or cognitive issues.[3][6]
When Should You Talk to a Doctor About Stopping?
Discontinue if severe bleeding, allergy (rash, swelling), or unexplained muscle weakness emerges. No withdrawal syndrome noted, but triglycerides rebound quickly. Regular monitoring advised every 3-6 months.[1][4]
[1]: Vascepa Prescribing Information (FDA)
[2]: REDUCE-IT Trial (NEJM, 2019)
[3]: FDA Sentinel Report on Vascepa (2023)
[4]: Drugs.com Vascepa Side Effects
[5]: EVAPORATE Trial (JAHA, 2020)
[6]: Amarin Safety Updates (Investor Reports)